2005;293:349 57. 429. Dracup K, Alonzo AA, Atkins JM, et al. The physician s role in mini- mizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program.Working Group on Educational StrategiesTo Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med. 1997;126:645 51. 430. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122:2619 633. 431. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909 17. 432. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplate- let therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634 40. 433. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4:522 34. 434. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syn- drome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010;103:13 28. 435. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433 41. 436. You JJ, Singer DE, Howard PA, et al. 